Vincent Camus

Hematologist, MD, PhD

[Côme Bommier @ComeBommier]

An important effort was made by @LysaLymphoma investigators to demonstrate feasibility of associating ctDNA + PET in EOT assessment in 1L PMBL and 1L FL.

Congrats to @VincentCamus76 and Alexis Claudel 🎉

Proud of you guys!!
#ICML18

[Blood Advances @BloodAdvances]

TAFA combined with LEN showed limited efficacy after CAR T-cell failure in a high-risk population. https://t.co/25bgAqc3B8 #lymphoidneoplasia

[Raul Cordoba, MD, PhD @DrRaulCordoba]

@Borjaibanez1 to present the update on @resilienceH2020 clinical trial to prevent anthracycline-induced cardiotoxicity in patients with #lymphoma with the intervention of remote ischemic precondition regimen #CARDIOTOX2024 #CardioOnc

[Blood Advances @BloodAdvances]

Outcomes were comparable between the TAFA-LEN combination and other treatments for the first progression after CAR T-cell therapy. https://t.co/GteBMfGHML #lymphoidneoplasia

[Vincent Camus @VincentCamus76]

On behalf of my co-authors, I’m excited to announce that our DESCAR-T/LYSA article, “Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy,” is now published on #Bloodadvances ! https://t.co/8NlXdctMmE

[British Journal of Haematology @BrJHaem]

Toward a paradigm shift in prognostication and treatment of early-stage Hodgkin lymphoma
https://t.co/h9waDhbcsf

[Journal of Clinical Oncology @JCO_ASCO]

With 6-year FU ‘Ro-CHOP’ study still negative but potential benefit of HDACi in TFH-PTCL and BV+chemo at relapse ➡️ https://t.co/3dWqXPXQTg @LysaLymphoma @BachyEmmanuel @VincentCamus76

[Jonathan Friedberg @DrJFriedberg]

Final Analysis of the Ro-CHOP Trial in T-cell lymphoma: In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm. @JCO_ASCO https://t.co/PHrlYophq3

[ELI @EliLymphoma]

The winners of the Bertrand Coiffier 2023 award, Jean Lemoine and Vincent Camus, presented their projects at the LYSA meeting @LysaLymphoma

[Vincent Camus @VincentCamus76]

Very honored to have received one of the two Bertrand Coiffier 2023 Awards. Thank you very much to @EliLymphoma , @LysaLymphoma and the International Jury for awarding this prize allowing me to realize a research mobility in Prof. Davide Rossi's lab at the @IOR_Bellinzona

[Vincent Camus @VincentCamus76]

On behalf of my co-authors, I am pleased to let you know that the final version of the PMBL LYSA BIO article « High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma » is now available on Blood Advances

https://t.co/dCCQzYTHmf

[ELI @EliLymphoma]

Next week, hybrid ELI workshop : “Genomics of lymphoma: from basic to clinical use”

[VJHemOnc @VJHemOnc]

Today marks the last day of ICML - we can't believe it's already over!

Thank you to the congress organizers for having us onsite & to all the experts who took time to speak with us!

Check out our interviews on https://t.co/O9p0vDBrzw 🎥

@icmlugano #LymSM #17ICML

[Graham Collins @graham74GC]

Camus et al - 5y FU Ro-CHOP in PTCL
• overall no benefit RoCHOP v CHOP
• possible benefit in Tfh
• many diff regimens at relapse
• v poor PFS2 & OS2
• poss benefit of BV-cont regimens at relapse
Great @LysaLymphoma study
#17ICML

[Vincent Camus @VincentCamus76]

Nouvelle publication à partager

High prevalence of pre-existing sarcopenia in critically ill patients with hematological malignancies admitted to the ICU

https://t.co/MlQN8rfFB5

[Vincent Camus @VincentCamus76]

Dans les coulisses du centre Becquerel, à Rouen : quelle stratégie pour soigner un cancer ? https://t.co/21f5gm96hc via @paris_normandie

[Vincent Camus @VincentCamus76]

Je vous invite à lire cette nouvelle review qui propose un état de l’art sur le diagnostic, la biologie et la prise en charge de ce lymphome très particulier qu’est le lymphome B primitif du médiastin https://t.co/gqhurlitHe

[Vincent Camus @VincentCamus76]

Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy - A retrospective study
#centrebecquerel https://t.co/xtUA6I9tgs

[RESILIENCE H2020 @resilienceH2020]

This has been my first large meeting 😅 thx for presenting me in society @Borjaibanez1 @TeresaLpezFdez1 @escardio @CNIC_CARDIO @Kersten_MJ @DrRaulCordoba @VincentCamus76 @Joukesmink @elsapacella @CIBER_CV @knowyournodes